Product image of Ibandronic Acid Mylan (Ibandronic Acid) supplied by GNH India

Ibandronic Acid Mylan

Active Ingredient:
Ibandronic Acid
Origin:
EU

Ibandronic Acid Mylan (Ibandronic Acid)

Ibandronic Acid, the active ingredient in Ibandronic Acid Mylan, is a bisphosphonate presented as a tablet for oral use. It treats osteoporosis in postmenopausal women and patients receiving glucocorticoids.

GNH India supplies Ibandronic Acid Mylan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Mcdermott Laboratories Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ibandronic Acid is a bisphosphonate used to manage bone‑loss conditions within the osteoporosis disease family.

  • Postmenopausal osteoporosis: reduces the risk of vertebral and non‑vertebral fractures.
  • Glucocorticoid‑induced osteoporosis: improves bone mineral density and lowers fracture incidence.

How It Works

  • Ibandronic Acid binds to hydroxyapatite crystals on bone surfaces, preferentially localising at sites of active remodeling. When osteoclasts attach to the drug‑coated bone, it is internalised, disrupting the mevalonate pathway, inducing osteoclast apoptosis and thereby decreasing bone resorption.

Side Effects

Ibandronic Acid may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

  • Upper gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
  • Musculoskeletal pain: transient bone, joint or muscle aches.
  • Flu‑like symptoms: fever, chills or malaise after the first dose.
  • Headache: mild to moderate intensity.
  • Transient serum calcium reduction: mild hypocalcaemia.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw: persistent exposed bone in the oral cavity.
  • Atypical femoral fractures: low‑energy subtrochanteric or femoral shaft fractures.
  • Severe renal impairment: acute kidney injury or worsening of chronic kidney disease.
  • Severe hypersensitivity: rash, angioedema or anaphylaxis.
  • Esophageal ulceration or erosion: severe throat pain or difficulty swallowing.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

  • Renal function: assess creatinine clearance and avoid use in severe renal impairment.
  • Gastrointestinal health: screen for active esophageal disorders; advise patients to remain upright after dosing.
  • Calcium/vitamin D status: ensure adequate supplementation to minimise hypocalcaemia.
  • Concomitant medications: review use of NSAIDs, corticosteroids or other agents that may irritate the esophagus.
  • Pregnancy and lactation: avoid use due to unknown safety; discuss alternatives with the prescriber.
  • Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Ibandronic Acid can interact with several drug classes, affecting absorption or renal handling.

Major Interactions (Avoid)

  • Antacids containing calcium, magnesium, aluminum or iron: bind the drug and markedly reduce oral absorption.
  • Proton pump inhibitors (PPIs): may increase risk of esophageal irritation when taken without proper timing.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive risk of gastrointestinal ulceration.
  • Loop or thiazide diuretics: may exacerbate hypocalcaemia; monitor serum calcium.
  • Renal‑clearing drugs (e.g., aminoglycosides, cisplatin): potential for additive nephrotoxicity; assess renal function regularly.

Frequently Asked Questions

Ibandronic Acid Mylan is prescribed to treat osteoporosis, specifically in postmenopausal women and in patients who develop bone loss due to long‑term glucocorticoid therapy. It works by reducing bone resorption, thereby lowering the risk of fractures.

The drug binds tightly to bone mineral at sites of active remodeling. When osteoclasts attach to this drug‑coated bone, Ibandronic Acid is taken up by the cells, disrupting a key biochemical pathway that leads to osteoclast apoptosis, which in turn decreases bone breakdown.

The dosing regimen for Ibandronic Acid Mylan is determined by the prescribing physician based on the patient’s clinical condition, renal function and other individual factors. Patients should follow the prescriber’s instructions and the product label precisely.

The safety of Ibandronic Acid in pregnancy and lactation has not been established. It is generally avoided in these populations, and alternative therapies should be discussed with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ibandronic Acid belongs to the bisphosphonate class, similar to alendronate and risedronate. Compared with some alternatives, it is often administered less frequently (e.g., monthly dosing) and has a comparable efficacy in reducing vertebral fractures, though individual response and tolerability may vary.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually with a full glass of plain water on an empty stomach. Patients should remain upright for at least 30 minutes after ingestion and avoid eating, drinking, or taking other medications during that time.

Serious adverse events include osteonecrosis of the jaw, atypical femoral fractures, severe renal impairment and acute hypersensitivity reactions. Patients should report persistent jaw pain, unusual thigh or groin pain, sudden loss of kidney function, or signs of an allergic reaction to their healthcare provider immediately.

Individuals with severe renal impairment (creatinine clearance <30 mL/min), active esophageal disorders, known hypersensitivity to bisphosphonates, or those who are pregnant or breastfeeding should avoid using Ibandronic Acid Mylan unless advised otherwise by a qualified clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ibandronic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT